Company profile
Supernus Pharmaceuticals, Inc.
NASDAQ: SUPN · Healthcare · Drug Manufacturers - Specialty & Generic
#186 of 1,422 Healthcare companies by revenue54th-percentile growth
EA Score
76B+FH 72DQ 88GM 62SS 79
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$776.8M
Rev growth YoY (TTM)
+16.3%
Net income (FY)
-$38.5M
Employees
778
as of 2026-08-08
Market cap
$2.8B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$719.0M$719.0M2025
Net income-$38.5M-$38.5M2025
Operating income-$62.3M-$62.3M2025
Total assets$1.5B$1.5B2025
Liabilities$390.9M$390.9M2025
Equity$1.1B$1.1B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product47%
Qelbree23%
GOCOVRI11%
Collaboration Revenue4%
APOKYN4%
Trokendi Xr3%
By geography
Not disclosed.
The read
What is Supernus Pharmaceuticals, Inc.’s revenue?
Supernus Pharmaceuticals, Inc. booked $719.0M in FY2025 revenue, growing 8.6% year over year — about the middle of the pack among Healthcare companies we track, at a -5.4% net margin.
Peers · Healthcare
NeoGenomics, Inc.72BPacira BioSciences, Inc.78B+Amphastar Pharmaceuticals, Inc.77B+Sienna Senior Living Inc.75B+Avanos Medical, Inc.73BUltragenyx Pharmaceutical Inc.58CNeighbors
Montgomery →Key facts
CEOJack A. Khattar
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersRockville, MD
ExchangeNASDAQ: SUPN
Employees778
IPO date2012-05-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.